ACTU

Actuate is a pre-revenue, clinical-stage biopharma whose entire value rests on one asset, the GSK-3β inhibitor elraglusib. The bull case got materially stronger at ASCO GI in January 2026: the randomized Phase 2 Actuate-1801 study in first-line metastatic pancreatic cancer (mPDAC, 286 patients) met its primary endpoint with a statistically significant median-OS benefit (10.1 vs 7.2 months, p=0.02, HR=0.62), near-doubling of 12-month survival (44.4% vs 22.3%) and a ~5x lift in 24-month survival. In a graveyard indication where almost nothing works, a positive, statistically significant survival signal is a genuine de-risking event and the reason this $1.52 stock is not simply an 'avoid.'

But the balance sheet undercuts the science. The company holds just $13.2M cash against a $19.2M annual operating burn — well under twelve months of runway — while carrying a $155M accumulated deficit and a -280% ROE. Management states plainly it 'will continue to incur substantial and increasing operating losses,' that oral-tablet and pediatric programs advance only 'subject to future funding,' and that a Phase 3 in mPDAC is unfunded. Shares outstanding already grew 21.4% in FY2025; financing the next phase almost certainly means a large, dilutive raise or a partnering deal at a low base. The FY2025 R&D drop (-44.9%) and the huge equity swing (+7,505%, off a near-zero base) reflect a company managing to survive, not scaling. Note also the numbers here are the antithesis of the 'consistent, profitable growth' the framework rewards: no revenue in any year, three straight ~$22-27M net losses.